The DOI matches its Crossref record.
Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer
Abstract
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Dec 2002Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer WILLIAM BERRY, SHAKER DAKHIL, MANUEL MODIANO, MARYANN GREGURICH, and LINA ASMAR WILLIAM BERRYWILLIAM BERRY , SHAKER DAKHILSHAKER DAKHIL , MANUEL MODIANOMANUEL MODIANO , MARYANN GREGURICHMARYANN GREGURICH , and LINA ASMARLINA ASMAR View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64163-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We compared median time to treatment failure of men with asymptomatic, hormone refractory, progressive prostate cancer treated with mitoxantrone plus prednisone versus prednisone alone. Materials and Methods: In a multicenter phase III trial 120 men with asymptomatic, progressive, hormone refractory prostate cancer were randomly assigned to treatment with mitoxantrone and prednisone or prednisone alone. Patients received 12 mg./m.2 mitoxantrone intravenously once every 3 weeks for 6 cycles and 5 mg. prednisone twice daily with or without mitoxantrone. Time to treatment failure was assessed as an aggregate end point comprised of time to disease progression, time to toxicity or death, or time to initiation of alternate therapy. Results: Median followup was 21.8 months. Median time to treatment failure and median time to progression were the same: time to treatment failure and time to progression in the mitoxantrone and prednisone group was 8.1 months compared to 4.1 months in the prednisone alone group (p = 0.017 versus p = 0.018). More patients (27 or 48%) treated with mitoxantrone and prednisone achieved a 50% or greater reduction in prostate specific antigen levels than those who received only prednisone (15 or 24%, p = 0.007). There was no significant difference in median survival between the 2 groups, which was 23 and 19 months, respectively. Death was mainly attributable to disease progression. Conclusions: Patients with hormone refractory prostate cancer who are asymptomatic but had progressive disease had a significantly higher response rate when treated with mitoxantrone and prednisone as demonstrated by the 50% or greater decrease in prostate specific antigen compared to treatment with prednisone alone. Time to treatment failure was significantly prolonged in the chemotherapy treated group but survival rates were not different. References 1 : Drug development in prostate cancer. Semin Oncol1999; 26: 217. Google Scholar 2 : Chemotherapy for hormone refractory prostate cancer. Urol Clin North Am1999; 26: 323. Google Scholar 3 : Current clinical trial design issues in hormone-refractory prostate carcinoma. Cancer1996; 82: 2093. Google Scholar 4 : Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer1994; 74: 100. Google Scholar 5 : Taxol in advanced hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer1993; 72: 2457. Google Scholar 6 : Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol2000; 163: 1481. Abstract, Google Scholar 7 : Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol1999; 26: 55. Google Scholar 8 : Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol1999; 17: 2506. Google Scholar 9 : Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol1999; 17: 1654. Google Scholar 10 : Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780 (Cancer and Leukemia Group B). J Clin Oncol2001; 19: 2509. Google Scholar 11 : Other chemotherapy regimens including mitoxantrone and suramin. Semin Urol Oncol1997; 15: 20. Google Scholar 12 : Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol1994; 12: 689. Google Scholar 13 : Mitoxantrone. Drug Intell Clin Pharm1986; 20: 97. Google Scholar 14 : Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol1996; 14: 1756. Google Scholar 15 : Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging1997; 10: 473. Google Scholar 16 : 14-Day c
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Ruiz de Porras, V., Font, A., & Aytes, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.033 · Cited by 65
Metadata
- Authors
- BERRY, W., DAKHIL, S., MODIANO, M., GREGURICH, M., & ASMAR, L.
- Venue
- Journal of Urology
- Published
- 2002-12
- Volume
- 168
- Issue
- 6
- Pages
- 2439-2443
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W4296140011
- Cited by
- 168
- References
- 0
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer. https://app.cochat.ai/papers/10.1016/s0022-5347(05)64163-8
- The paper
- BERRY, W., DAKHIL, S., MODIANO, M., GREGURICH, M., & ASMAR, L. (2002). Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)64163-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.